---
bibliography: 'morinlab.bib'

link-citations: true
---

# Welcome to Lymphopedia!


## Overview

This is a comprehensive catalogue of genes that have been nominated as *recurrently mutated* in one of several common B-cell lymphomas. Each gene is categorized based on the level and quality of supporting data in the original study and other comparable datasets. Details for each gene can be found on their respective pages. The novel genes nominated by each study can be found on the study-centric pages.

To get started, select one of the gene lists from the table below then select the `gene page` link for any gene in the table or explore the genes nominated by [individual studies](Papers).  

## A brief history of B-cell lymphoma genes

```mermaid
---
config:
  sankey:
    showValues: false
    linkColor: target
    width: 775
    height: 1300
    nodeAlignment: left
---
sankey-beta
Albuquerque 2017, DLBCL Tier 1, 3
Lohr 2012, DLBCL Tier 1, 3
Lohr 2012, DLBCL Tier 2, 1
Pasqualucci 2001, DLBCL Tier 1, 2
Pasqualucci 2001, DLBCL Tier 2, 2
Mareschal 2016, DLBCL Tier 1, 2
Arthur 2018, DLBCL Tier 1, 8
Arthur 2018, DLBCL Tier 2, 12
Morin 2016, DLBCL Tier 1, 2
Morin 2013, DLBCL Tier 1, 11
Morin 2013, DLBCL Tier 2, 29
Pasqualucci 2011, DLBCL Tier 1, 2
Hubschmann 2021, DLBCL Tier 1, 3
Hubschmann 2021, DLBCL Tier 2, 20
Chapuy 2018, DLBCL Tier 1, 2
Chapuy 2018, DLBCL Tier 2, 17
Pasqualucci 2011, DLBCL Tier 1, 3
Pasqualucci 2011, DLBCL Tier 2, 4
Reddy 2017, DLBCL Tier 1, 7
Reddy 2017, DLBCL Tier 2, 53
Zhang 2013, DLBCL Tier 1, 11
Zhang 2013, DLBCL Tier 2, 8
Schmitz 2018, DLBCL Tier 1, 7
Schmitz 2018, DLBCL Tier 2, 9
Morin 2011, DLBCL Tier 1, 24
Morin 2011, DLBCL Tier 2, 1
DLBCL, DLBCL-exome, 7
DLBCL-exome, Pasqualucci 2011, 7
DLBCL, DLBCL-exome, 19
DLBCL-exome, Chapuy 2018, 19
DLBCL, DLBCL-WGS, 23
DLBCL-WGS, Hubschmann 2021, 23
DLBCL, DLBCL-WGS/exome, 2
DLBCL, DLBCL-exome, 2
DLBCL-exome, Pasqualucci 2011, 2
DLBCL, DLBCL-RNA-seq/WGS, 25
DLBCL-RNA-seq/WGS, Morin 2011, 25
DLBCL, DLBCL-exome, 19
DLBCL-exome, Zhang 2013, 19
DLBCL, DLBCL-exome, 16
DLBCL-exome, Schmitz 2018, 16
DLBCL, DLBCL-exome, 60
DLBCL-exome, Reddy 2017, 60
DLBCL, DLBCL-exome, 4
DLBCL-exome, Lohr 2012, 4
DLBCL, DLBCL-exome, 3
DLBCL-exome, Albuquerque 2017, 3
DLBCL, DLBCL-exome, 2
DLBCL-exome, Morin 2016, 2
DLBCL, DLBCL-WGS, 40
DLBCL-WGS, Morin 2013, 40
DLBCL, DLBCL-exome, 2
DLBCL-exome, Mareschal 2016, 2
DLBCL, DLBCL-WGS, 20
DLBCL-WGS, Arthur 2018, 20
DLBCL, DLBCL-Sanger, 4
DLBCL-Sanger, Pasqualucci 2001, 4
Pasqualucci 2011, FL Tier 1, 2
Hubschmann 2021, FL Tier 1, 2
Hubschmann 2021, FL Tier 2, 15
Krysiak 2017, FL Tier 1, 17
Krysiak 2017, FL Tier 2, 5
Morin 2011, FL Tier 1, 14
Morin 2011, FL Tier 2, 1
Okosun 2016, FL Tier 1, 2
Russler-germain 2023, FL Tier 1, 1
Russler-germain 2023, FL Tier 2, 19
FL, FL-WGS, 17
FL-WGS, Hubschmann 2021, 17
FL, FL-exome, 2
FL-exome, Pasqualucci 2011, 2
FL, FL-RNA-seq/WGS, 15
FL-RNA-seq/WGS, Morin 2011, 15
FL, FL-exome, 22
FL-exome, Krysiak 2017, 22
FL, FL-exome, 20
FL-exome, Russler-germain 2023, 20
FL, FL-WGS, 2
FL-WGS, Okosun 2016, 2
Muppidi 2014, BL Tier 1, 1
Muppidi 2014, BL Tier 2, 2
Panea 2019, BL Tier 1, 4
Panea 2019, BL Tier 2, 36
Thomas 2023, BL Tier 1, 2
Thomas 2023, BL Tier 2, 3
Grande 2019, BL Tier 1, 9
Grande 2019, BL Tier 2, 4
Richter 2012, BL Tier 1, 5
Burkhardt 2022, BL Tier 2, 25
Schmitz 2012, BL Tier 1, 3
Schmitz 2012, BL Tier 2, 16
Love 2012, BL Tier 1, 3
Love 2012, BL Tier 2, 56
BL, BL-RNA-seq/exome, 40
BL-RNA-seq/exome, Panea 2019, 40
BL, BL-Sanger, 3
BL-Sanger, Muppidi 2014, 3
BL, BL-WGS, 5
BL-WGS, Thomas 2023, 5
BL, BL-panel, 25
BL-panel, Burkhardt 2022, 25
BL, BL-WGS, 13
BL-WGS, Grande 2019, 13
BL, BL-RNA-seq/WGS/exome, 5
BL-RNA-seq/WGS/exome, Richter 2012, 5
BL, BL-exome, 59
BL-exome, Love 2012, 59
BL, BL-RNA-seq, 19
BL-RNA-seq, Schmitz 2012, 19
MCL, MCL-WGS/exome, 27
MCL-WGS/exome, Bea 2013, 27
MCL, MCL-WGS/exome, 7
MCL-WGS/exome, Pararajalingam 2020, 7
MCL, MCL-WGS, 5
MCL-WGS, Nadeu 2020, 5
MCL, MCL-exome, 28
MCL-exome, Zhang 2014, 28
Zhang 2014, MCL Tier 1, 2
Zhang 2014, MCL Tier 2, 26
Bea 2013, MCL Tier 1, 11
Bea 2013, MCL Tier 2, 16
Nadeu 2020, MCL Tier 1, 3
Nadeu 2020, MCL Tier 2, 2
Pararajalingam 2020, MCL Tier 1, 6
Pararajalingam 2020, MCL Tier 2, 1
MZL, MZL-exome, 28
MZL-exome, Jallades 2017, 28
MZL, MZL-Sanger, 5
MZL-Sanger, Rossi 2011, 5
MZL, MZL-exome/panel, 31
MZL-exome/panel, Spina 2016, 31
MZL, MZL-exome, 21
MZL-exome, Rossi 2012, 21
MZL, MZL-panel, 2
MZL-panel, Vandenbrand 2017, 2
MZL, MZL-Panel, 2
MZL-Panel, Yan 2012, 2
MZL, MZL-exome, 7
MZL-exome, Parry 2013, 7
Vandenbrand 2017, MZL Tier 2, 2
Rossi 2012, MZL Tier 1, 10
Rossi 2012, MZL Tier 2, 11
Yan 2012, MZL Tier 1, 2
Parry 2013, MZL Tier 2, 7
Spina 2016, MZL Tier 1, 8
Spina 2016, MZL Tier 2, 23
Jallades 2017, MZL Tier 1, 2
Jallades 2017, MZL Tier 2, 26
Rossi 2011, MZL Tier 1, 4
Rossi 2011, MZL Tier 2, 1

```

## Gene lists


|Entity|Tier 1 (high-confidence)|Tier 2 (low-confidence)|
|:-:|:-:|:-:|
|BL|[29 genes](BL_genes#tier-1-bl-genes)|[152 genes](BL_genes#tier-2-bl-genes)|
|DLBCL|[127 genes](DLBCL_genes#tier-1-dlbcl-genes)|[215 genes](DLBCL_genes#tier-2-dlbcl-genes)|
|FL|[66 genes](FL_genes#tier-1-fl-genes)|[50 genes](FL_genes#tier-2-fl-genes)|
|PMBL|[76 genes](PMBL_genes#tier-1-pmbl-genes)|[82 genes](PMBL_genes#tier-2-pmbl-genes)|
|MCL|[23 genes](MCL_genes#tier-1-mcl-genes)|[46 genes](MCL_genes#tier-2-mcl-genes)|
|MZL|[42 genes](MZL_genes#tier-1-mzl-genes)|[74 genes](MZL_genes#tier-2-mzl-genes)|

\* *PMBL gene list includes genes attributed to classical Hodgkin lymphoma or marginal grey-zone lymphoma*

## B-cell Lymphoma aSHM targets

[hg19 coordinates](ashm)

[hg38 coordinates](ashm_hg38)


## Originating studies for all B-cell lymphoma genes

### [All studies](Papers.md)

### Studies selected for QC

|Study|Entity|Novel Tier 1|Genes that failed QC|
|:-:|:-:|:-:|:-:|
|[@loveGeneticLandscapeMutations2012](papers/loveGeneticLandscapeMutations2012)|BL|3|47 (80%)|
|[@morinMutationalStructuralAnalysis2013](papers/morinMutationalStructuralAnalysis2013)|DLBCL|11|TBD|
|[@reddyGeneticFunctionalDrivers2017](papers/reddyGeneticFunctionalDrivers2017)|DLBCL|7|29 (56%)|
|[@paneaWholeGenomeLandscape2019](papers/paneaWholeGenomeLandscape2019)|BL|4|22 (55%)|
|[@hubschmannMutationalMechanismsShaping2021b](papers/hubschmannMutationalMechanismsShaping2021b)|DLBCL,FL|4|3 (9%)|

## Categorization

### Gene Tiers

**Tier 2** - Any gene described as significantly or recurrently mutated in one or more types of B-cell lymphoma is initially assigned to Tier 2 for that entity. The study describing the mutation of that gene in a particular entity is considered the originating study. 

**Tier 1** - Genes can transition to Tier 1 only after additional studies have demonstrated the recurrence of mutations in the same entity.  

### Gene Designations

**aSHM** - Denotes genes as affected by aberrant somatic hypermutation (aSHM). Tier 1 and Tier 2 genes can have this designation, respectively abbreviated as *1-a* and *2-a*. For example, see [BCL7A](BCL7A).

**Fail** - Some studies with large additions to Tier 2 lists have undergone manual review of the primary data. If the majority of mutations in a gene fail QC, the gene will be given the designation *2-F*. For example, see [MARK1](MARK1).


## B-cell lymphoma mutation browser

![](images/proteinpaint/FOXO1_NM_002015.svg)

## Gene expression distributions across B-cell lymphomas

![](images/gene_expression/FOXO1_by_pathology.svg)

## References

